Navigation Links
Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Date:3/13/2008

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that Senior Vice President and CFO William R. LaRue will present a corporate overview on Thursday, March 20, 2008 at 11:00am Eastern Time (8:00am Pacific Time) during the Cowen and Company 28th Annual Health Care Conference at the Marriott Copley Place in Boston, Massachusetts.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com. To access the presentation, click on the Investor Relations tab and then click on the link entitled "Events and Presentations" on the left side of the screen. A replay of the webcast will available approximately one hour after the live webcast concludes and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals,
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
2. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
3. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
9. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. NPS Pharmaceuticals Reports 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Asia-Pacific , and Rest of ... 2012 through 2020. Market data and analytics are derived from ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Electric Power Co. and Wisconsin Gas LLC, collectively known ... for relationship management software to automate, track and execute ... than 1.1 million electric customers in Wisconsin and Michigan's ... customers in Wisconsin. As part of a sourcing transformation, ...
... MILWAUKEE - Niceware International, a supplier ... on Monday they have introduced version 4.0 of their ... include support for reading and programming radio frequency identification ... The system's modules are also integrated with Windows programs ...
... services provider, announced Tuesday a new market campaign in ... the campaign will expand the PDS presence in the ... Specialized Technology Partner Certifications from Cisco in the three ... Communications, IP Communications Express, and Wireless. In addition, PDS ...
Cached Biology Technology:
(Date:8/19/2014)... improve students, chances of completing introductory biology courses ... (UH) implemented a comprehensive student success program, employing ... , Through a grant from the Texas ... Biology and Biochemistry embarked on a pilot program ... non-majors and "Introductory Biology" for science majors. These ...
(Date:8/19/2014)... . Wind ... large amount of electricity is to be produced with renewable ... be stored during productive periods so that these fluctuations can ... adequate for the purpose. Science and industry are therefore working ... systems that used to be too expensive or unsophisticated to ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... of breast cancer patients have tumours that show rapid ... in all of these cases is the presence of ... membranes. Consequently, these aggressive tumours are referred to as ... IRB Barcelona headed by ICREA researcher Roger Gomis, have ...
... , This release is available in ... unsightly vegetable patches, they can also result in extensive ... this garden pest are similar to those involved in ... Breeding Research in Cologne and the University of Zurich ...
... experts from the European Society on Clinical and ... the International Osteoporosis Foundation (IOF) have published a ... femoral (upper thigh bone) fractures and long-term treatment ... common drug therapy for osteoporotic fracture prevention, prescribed ...
Cached Biology News:The most aggressive forms of breast cancer elude cellular control mechanisms in order to expand 2Mildew-resistant and infertile 2IOF and ESCEO position on atypical femoral fractures and long-term bisphosphonate use 2
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: